Volume 1,Issue 3
Clinical Study on Modified Liujunzi Decoction in the Treatment of Precancerous Lesions of Gastric Cancer with Spleen-Stomach Weakness Syndrome
Objective: To observe the clinical efficacy of Modified Liujunzi Decoction in the treatment of precancerous lesions of gastric cancer (PLGC) with spleen-stomach weakness syndrome, as well as its impact on gastric mucosal manifestations under gastroscopy and pathological changes. Methods: Sixty patients with PLGC with spleen-stomach weakness syndrome were selected and randomly divided into a treatment group and a control group, with 30 patients in each group. The treatment group received orally administered Modified Liujunzi Decoction, while the control group was treated with folic acid tablets and Teprenone Capsules. After 12 weeks of intervention, the effects on clinical symptoms of PLGC, gastric mucosal manifestations under gastroscopy, and pathological changes were observed. Results: According to the comprehensive assessment of the efficacy of major traditional Chinese medicine symptoms, the total effective rate of symptom score improvement in the treatment group was 83.3%, which was significantly higher than that of the control group. The total effective rate of gastroscopic efficacy was 70.0%. The treatment group was superior to the control group in terms of improvement in atrophy and intestinal metaplasia scores for pathological changes (P < 0.05). Conclusion: Modified Liujunzi Decoction exhibits significant efficacy in the treatment of PLGC with spleen-stomach weakness syndrome, markedly improving clinical symptoms and pathological conditions.
[1] Ma ZL, 2023, The Adjuvant Therapeutic Effect of Modified Liu Jun Zi Tang on Patients after Endoscopic Submucosal
Dissection for Early Gastric Cancer. Primary Level Chinese Medicine, 2(10): 45–50. https://doi.org/10.20065/j.cnki.
btcm.20230216
[2] Tang XR, Hu J, Zhao PF, 2023, Effects of Modified Xiang Sha Liu Jun Zi Tang on Intestinal Mucosal Barrier and Immune
Status of Patients with Gastric Cancer after Surgery. China Medicine, 18(12): 1874–1878.
[3] Luo WQ, Tu WL, Hong YJ, et al., 2024, Research on the Mechanism of Liu Jun Zi Tang in the Treatment of Chronic
Atrophic Gastritis Based on Network Pharmacology and Experimental Verification. Journal of Traditional Chinese
Medicine, 52(1): 49–57. https://doi.org/10.19664/j.cnki.1002-2392.210
[4] Xu ZG, Li H, 2021, Clinical Efficacy and Safety of Modified Liu Jun Zi Tang in Adjuvant Treatment of Spleen-qi
Deficiency Type Advanced Gastric Cancer. Journal of Clinical Rational Drug Use, 14(26): 24–26. https://doi.org/10.15887/
j.cnki.13-1389/r.2021.26.008
[5] Cheng S, Zhang XX, Liang L, et al., 2021, Regulatory Effect of Modified Liu Jun Zi Tang on Immune Function,
Nutritional Status, and Intestinal Microecology in Patients with Qi and Blood Deficiency Syndrome of Advanced Gastric
Cancer. Chinese Journal of Experimental Traditional Medical Formulae, 27(5): 98–104. https://doi.org/10.13422/j.cnki.
syfjx.20210543
[6] Lei XJ, Zeng HZ, Feng LJ, et al., 2019, Clinical Study on Modified Liu Jun Zi Tang Combined with Electroacupuncture in
the Treatment of Precancerous Lesions of Stomach Cancer with Qi Deficiency and Blood Stasis. New Chinese Medicine,
51(5): 107–109. https://doi.org/10.13457/j.cnki.jncm.2019.05.031